company? Let’s change
that.
At Krystal Biotech, Inc., our mission is to make a meaningful difference in the lives of underserved patient populations suffering from debilitating skin diseases. We work to accomplish this goal through scientific innovation and operational excellence, believing that "nature operates in the shortest way possible" (Aristotle). We are a clinical-stage gene therapy company using our proprietary, engineered virus vector platform to develop effective and innovative treatments for skin diseases. While we are initially developing topical and intradermal "off-the-shelf" novel therapies for rare and orphan dermatological indications, we are expanding the use of our pioneering gene technology to target and treat other rare diseases. The diseases for which we develop therapies provide inspiration for our day-to-day activities. There is clarity in purpose, a collective empathy driving us forward. Krystal was named after this clarity — a simple realization that we can do better. In doing so, we extend gratitude to the patients, caregivers, advocates and physicians dedicated to the diseases which unite us in purpose. Community Guidelines: http://bit.ly/KrystalCG
Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue of approximately $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD.
We offer solutions that bridge artificial intelligence (AI) and machine learning (ML), physiologically based pharmacokinetics, quantitative systems pharmacology/toxicology, and population PK/PD modeling approaches. Our technology is licensed and applied by major pharmaceutical, biotechnology, chemical, and consumer goods companies, and regulatory agencies worldwide.
Viatris is a global pharmaceutical company formed in 2020 through the combination of Mylan and Upjohn, a legacy division of Pfizer.
PeriphaGen is a biopharmaceutical company whose corporate objective is the development of first in class neuronal gene delivery products.
CytoAgents is a biotechnology company focused on the the treatment of COVID-19, Influenza and other viral infectious diseases.
Crystalplex provides fluorescent nanoparticle technology to the biomedical research, molecular diagnostic, and pathology markets.
StageMark develops and markets inflammatory diseases identification and monitoring solutions.
Renerva is a rapidly-growing and innovative medical device company.
SpIntellx is a computational pathology company developing novel AI tools based on spatial analytics.
Covestro is one of the world’s leading manufacturers of high-quality polymer materials and their components. With its innovative products, processes and methods, the company helps enhance sustainability and the quality of life in many areas. Covestro supplies customers around the world in key industries such as mobility, building and living, as well as the electrical and electronics sector. In addition, polymers from Covestro are also used in sectors such as sports and leisure, cosmetics and health, as well as in the chemical industry itself. The company is committed to becoming fully circular and is striving to become climate neutral by 2035 (scope 1, 2 and 3). Covestro generated sales of EUR 14.4 billion in fiscal 2023. At the end of 2023, the company had 48 production sites worldwide and employed approximately 17,500 people (calculated as full-time equivalents). Data protection information: https://www.covestro.com/en/social-media-privacy-statements
Consegna reformulates FDA approved drugs and creates new, long-acting injectable (LAI) medications.
Cook MyoSite is on a mission to make regenerative medicine a part of everyday medicine. As an industry leader in muscle cell technology, we’re establishing new paradigms for muscle-related disorders. Established in 2002, Cook MyoSite was created to guide the Cook Group organization into the expanding world of cellular technologies. We’re proud to be a part of the vibrant medical community in Pittsburgh, Pennsylvania.
Rubitection Inc is a medical device start-up focused on modernizing patient care and bringing awareness to the condition of pressure ulcers.
BlueSphere Bio is a novel TCXpress technology to unlock the potential of personalized T-cell therapy for the treatment of cancer .
Immunetrics takes a Quantitative Systems Pharmacology (QSP) approach to creating mechanistic mathematical models of biological systems, accelerating development of drugs, clinical diagnostics, and medical/commercial devices. We predict FDA-approved endpoints through in silico clinical trial simulations of acute or chronic inflammatory diseases. We deliver proprietary mathematical models encompassing biological pathways and interactions that span levels of detail from intracellular signaling pathways, cell-cell interactions, and organ systems. We also utilize complex analyses to help better understand your data and create novel hypotheses. Our robust bio-simulation platform represents 10+ years of work by our team of experts. Our capabilities allow our clients to bring their health care solutions to market more quickly, at a lower cost, and with decreased risk. Immunetrics was founded in 2001 and collaborates regularly with the most significant names in drug development, medical devices, and academia. Our team includes a cross disciplinary group of experts in physiology, molecular biology, immunology, computational biology, machine learning, and software engineering in a highly collaborative environment. We provide the expertise and experience to build functional models to inform our clients in their decision making process. Immunetrics' offices and computing center are conveniently located in South Side of Pittsburgh, PA. Our city is the home of the University of Pittsburgh Medical Center, with its world-class Critical Care Medicine, Surgery and Immunology departments; Carnegie Mellon University, with its world-renowned Engineering and Mathematics groups; and the Pittsburgh Supercomputing Center.
Citrine Informatics is the award-winning materials informatics platform for data-driven materials and chemicals development. It won the 2017 World Materials Forum Start-up Challenge, the 2018 AI Breakthrough award as the "Best AI-based Solution for Manufacturing," and 2020-2021 Cleantech 100 honors. The Citrine Platform combines smart materials data infrastructure and AI, which accelerates development of cutting-edge materials, facilitates product portfolio optimization, and codifies research IP, enabling its reuse and preventing its loss. Citrine's customers include Panasonic, Michelin, LANXESS, and some of the biggest and most respected names in the materials and chemicals industry in Asia, North America, and Europe.
Ariel Precision Medicine Creates innovative solutions to simplify the personalized treatment of complex disease.
Peptilogics is an early stage biotech developing a breakthrough technology platform in the antimicrobial segment.
BHS Biotechnology is a newly formed company, wholly owned by BioHybrid Solutions Holdings, Inc. (BHSH). All BHSH companies are endeavoring under the BioHybrid Solutions (BHS) banner. BHS’s vision is to deliver safe and effective biologic drugs to patients everywhere. Our mission is to harness science for the precise design and development of breakthrough biologic medicines. Our systematic in silico and in vitro process exerts ImmunoControl™ through our EpitopeSilencing™ process, improving pharmacokinetics and increasing the half-life of NanoArmored™ biologic therapeutics while maintaining activity. In addition, the ImmunoControlTM platform can be used for EpitopeTargeting™ and EpitopeAccentuation™ allowing for the discovery of new drugs against secondary, silent epitopes. Visit us at www.biohybridsolutions.com to learn more.
Work Your Passion. Live Your Purpose.